• 1
    Salem RB, Wilder BJ, Yost RL, et al. Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharmacol 1981; 38: 3547.
  • 2
    Spengler RF, Arrowsmith JB, Kilarski DJ, et al. Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med 1988; 148: 132933.
  • 3
    Louis S, Kutt H, McDowell F, et al. The cardiocirculatory changes caused by intravenous Dilantin and its solvent. Am Heart J 1967; 74: 5239.
  • 4
    TenHoor CN, Stewart BH. Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. Pharm Res 1995; 12: 18069.
  • 5
    Varia SA, Schuller S, Stella VJ. Phenytoin prodrugs. 4. Hydrolysis of various 3-(hydroxymethyl) phenytoin esters. J Pharm Sci 1984; 73: 107480.
  • 6
    Baron B, Henkin S, Knapp L. Incidence of complications with intravenous administration of fosphenytoin (Cerebyx) compared with Dilantin. Neurology 1995; 45 (suppl 4): 2489.
  • 7
    Knapp LE, Kugler AR, Eldon MA. Fosphenytoin: pharmacokinetics and administration. Emerg Med 1996; (suppl): 916.
  • 8
    Uthman BM, Wilder BJ, Ramsay RE. Intramuscular use of fosphenytoin: an overview. Neurology 1996; 46 (suppl 1): 5248.
  • 9
    Eldon MA, Loewen GR, Voigtman RE, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clin Pharmacol Ther 1996; 53: 212.
  • 10
    Eldon MA, Loewen GR, Voigtman RE, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects. Can J Neurol Sci 1993; 20: S180.
  • 11
    Kugler AR, Knapp LE, Eldon MA. Rapid attainment of therapeutic phenytoin concentrations following administration of loading doses of fosphenytoin: a meta-analysis. Neurology 1996; 46 (suppl): A176.
  • 12
    Lai CM, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester prodrug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin. Res Commun Mol Path Pharmacol 1995; 88: 5162.
  • 13
    Cerebyx (fosphenytoin sodium injection) package insert. Morris Plains , NJ : Parke-Davis, 1996.
  • 14
    Herbranson DE, Kriss-Denzigger P. Development and validation of a high performance liquid chromatography method for the determination of phenytoin prodrug (fosphenytoin) in solutions, parenteral formulations, and active drug substance. J Liquid Chromatogr 1993; 16: 114361.
  • 15
    Boucher BA, Bombassard AM, Rasmussen SN, et al. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. J Pharm Sci 1989; 78: 9303.
  • 16
    Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996; 46 (suppl 1): S37.
  • 17
    Gerber N, Mays DC, Donn KH, et al. Safety, tolerance, and pharmacokinetics of intravenous doses of phosphate ester of phenytoin 3-hydroxymethyl-5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol 1988; 28: 102332.
  • 18
    Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetic and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990; 40: 45660.
  • 19
    Boucher BA. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 1996; 16: 77791.